Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
「Stock God」 Serenity's Unwavering Support for SIVE: 191st Call Deems It the Most Attractive CPO Concept Stock

「Stock God」 Serenity's Unwavering Support for SIVE: 191st Call Deems It the Most Attractive CPO Concept Stock

BlockBeatsBlockBeats2026/05/26 12:47

BlockBeats News, May 26th. The newly emerged "Tech Small-Cap God" Serenity posted on social media, stating, "SIVE is the most attractive CPO (Co-Packaged Optics) concept stock to me. Even though it is highly volatile. You may have to wait until the next architectural-level change in photonics technology in the coming years to see a similar opportunity again. Among the core laser suppliers, most other companies have already reached a market capitalization of several hundred billion dollars. However, SIVE, as one of the key 'bottleneck' components in the CPO laser field, currently only has a market capitalization of $2.3 billion."


Financial reports usually only confirm the signals of capacity ramp-up that have already appeared, and most of the profits in the market are usually earned 'before the official confirmation,' rather than after the confirmation—this is a common rule in investment."


BlockBeats Note: Serenity is a highly influential senior trader on the Reddit forum WallStreetBets (WSB), with a year-to-date cumulative return rate of over 3,800%. Their core research results are consistently open and free, focusing on the key supporting links in the NVIDIA AI chip industry chain. By deeply combing through the indispensable "screw" components in the chip manufacturing and packaging process, they accurately identify the key chokepoints in the supply chain and explore upstream targets with scarcity and bargaining power to strategically position themselves. SIVE (Sivers Semiconductors) is the stock most mentioned by Serenity, with 190 previous calls. Since the first public call on March 16, 2026, it has surged 19.6 times.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

University of Michigan October Consumer Sentiment Index falls to a five-month low, with the Current Economic Conditions Indicator hitting a historic low

The University of Michigan’s Consumer Sentiment Index for October dropped to 46.3, below the market expectation of 47.6. The component reflecting current economic conditions decreased to 44.7, setting a new historical low, while the expectations component edged up to 47.3, marking its first rebound since July. Consumers’ one-year inflation expectations rose to 4.7%, and five-to-ten-year inflation expectations increased to 3.5%. According to the survey director, consumers from different political parties agree that the economic outlook has weakened compared to the beginning of the year.

华尔街见闻•2026/10/09 15:28

BUZZ - JPMorgan gives “overweight” rating to LSD-based therapies, Definium stock rises

Latest Updates, October 9th - ** Definium Therapeutics (DFTX.O) shares rose 7.4% to $36.7 ** If the rally holds, the stock is set for its biggest single-day gain since June ** JPMorgan initiated coverage of the stock with an "Overweight" rating and a target price of $84 ** The bank stated that Definium’s lead candidate drug, DT120 ODT, has the potential to transform the treatment landscape for neuropsychiatric disorders ** Based on current data, the institution considers DT120 ODT (an LSD oral formulation for the treatment of major depressive disorder and generalized anxiety disorder) to be a "de-risked asset" ** The new target price implies a 145.7% upside from the latest closing price ** "While changes in the macro environment may present potential investment risks to the sector, we believe the positives for Definium outweigh the negatives," the bank stated ** A period of "frequent landmark events" is expected ahead, including plans to submit a new drug application to the FDA in the first half of 2027 ** The bank projects that total sales of DT120 orally disintegrating tablets (ODT) will approach $5 billion by 2035 ** Including intraday volatility, the stock has more than doubled in value year-to-date (For the convenience of non-English speakers, Reuters has automated this report’s translation into several other languages. Due to possible errors in automated translation or lack of full context, Reuters does not guarantee the accuracy of the automated translation and provides it solely as a convenience to readers. Reuters accepts no liability for any damage or loss arising from the use of automated translation.)

路透社•2026/10/09 15:12